Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

NCT02504489 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

559

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Docetaxel + Plinabulin (DP)
DRUG: Docetaxel (D)

Sponsor

BeyondSpring Pharmaceuticals Inc.